In order to understand the relevance of biomarkers of biologically effective dose and early biologic effects in a broad public health context, it is critical to understand the biomarker-disease relationship. Although preliminary work can be carried out for some biomarkers in case-control studies, the potential for disease bias will always raise a concern about results from these studies. As such, prospective cohort studies carried out on large, generally healthy populations are the optimal approach to study the relationship between biomarker levels and disease risk. In these studies, biologic samples are collected from a defined population and banked, for later analysis the cohort is followed forward in time; subjects who develop disease are identified, and premorbid biomarker levels in these cases are then compared with those in unaffected subjects. Often, a nested case-control approach is used. Samples from cases and only a sample of the controls are analyzed, which considerably reduces the laboratory requirements and costs. These studies allow calculation of the relative risk, which provides an estimate of the increased risk in disease for a given level of a biomarker, and the etiologic fraction, which estimates the proportion of disease reflected by the biomarker. The consistent results across several, small cohort studies showing a positive relationship between chromosomal aberration levels in peripheral lymphocytes and subsequent cancer incidence or mortality suggest that at least some biomarkers of early biologic effect will prove to be relevant for predicting cancer risk. There win soon be over a minion subjects with blood samples banked in cohort studies in the U.S., Europe, and Asia. These studies will provide striking opportunities for the evaluation of the relationship between a wide range of biomarkers and disease risk over the coming years.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.